|
11,748
|
| 116364 |
Angiotensin I
|
|
increases_quantity of
|
Angiotensin (1-9)
|
via the catalytic activity of ACE2
|
| 116365 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
|
32333398
|
COVID-19
|
|
11,751
|
| 116895 |
Angiotensin (1-9)
|
|
increases_quantity of
|
Angiotensin (1-7)
|
via catalytic action of MME (NEP)
|
| 116897 |
MME
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
|
15283675
|
Endocrine
|
|
11,776
|
| 116581 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 116582 |
ACE
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
|
23463883
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
11,822
|
| 116793 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 116797 |
Angiotensin I
|
|
increases_quantity of
|
Angiotensin (1-9)
|
via the catalytic activity of ACE2
|
|
32336612
|
COVID-19
|
|
11,837
|
| 116868 |
Angiotensin I
|
|
increases_quantity of
|
Angiotensin (1-9)
|
via the catalytic activity of ACE2
|
| 116870 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 116873 |
ACE
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
| 116884 |
Angiotensin (1-9)
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
|
10969042
|
Endocrine
|
|
11,918
|
| 117247 |
Angiotensin (1-9)
|
|
increases_quantity of
|
Atrial natriuretic peptide
|
in atrium
|
|
27660028
|
Cardiovascular disease
|
|
11,919
|
| 117248 |
Angiotensin (1-9)
|
|
decreases_activity of
|
apoptotic process
|
in cardiomyocytes
|
| 117249 |
Angiotensin (1-9)
|
|
increases_activity of
|
AGTR2
|
in cardiomyocytes
|
| 117250 |
Angiotensin (1-9)
|
|
increases_activity of
|
AKT1
|
in cardiomyocytes
|
| 117251 |
Angiotensin (1-9)
|
|
decreases_activity of
|
ischemia-reperfusion injury
|
|
|
30048754
|
Cardiovascular disease
|
|
12,017
|
| 117742 |
Angiotensin (1-9)
|
|
decreases_activity of
|
pulmonary hypertension
|
|
| 117743 |
Angiotensin (1-9)
|
|
increases_activity of
|
AGTR2
|
|
| 117744 |
Angiotensin (1-9)
|
NOT |
increases_activity of
|
MAS1
|
|
| 117745 |
Angiotensin (1-9)
|
|
decreases_quantity of
|
TNF
|
in blood plasma
|
| 117746 |
Angiotensin (1-9)
|
|
decreases_quantity of
|
CCL2
|
in blood plasma
|
| 117747 |
Angiotensin (1-9)
|
|
decreases_quantity of
|
IL1B
|
in blood plasma
|
| 117748 |
Angiotensin (1-9)
|
|
decreases_quantity of
|
IL6
|
in blood plasma
|
| 117749 |
Angiotensin (1-9)
|
|
decreases_expression of
|
BAX
|
in lung
|
| 117750 |
Angiotensin (1-9)
|
|
decreases_expression of
|
BCL2
|
in lung
|
| 117751 |
Angiotensin (1-9)
|
|
decreases_expression of
|
CASP3
|
in lung
|
| 117752 |
Angiotensin (1-9)
|
|
decreases_expression of
|
CASP9
|
in lung
|
| 117753 |
Angiotensin (1-9)
|
|
decreases_activity of
|
inflammatory response
|
|
| 117754 |
Angiotensin (1-9)
|
|
decreases_activity of
|
pulmonary fibrosis
|
|
|
29962859
|
Cardiovascular disease
|
|
12,029
|
| 117995 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 117998 |
CTSA
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 118000 |
CPA3
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 118001 |
ACE
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
| 118003 |
ACE2
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
| 118005 |
MME
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
|
30934934
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
12,035
|
| 118123 |
Angiotensin (1-9)
|
|
increases_activity of
|
AGTR2
|
|
| 118124 |
Angiotensin (1-9)
|
|
decreases_activity of
|
cardiac hypertrophy
|
|
| 118125 |
Angiotensin (1-9)
|
|
decreases_activity of
|
cardiac fibrosis
|
|
| 118126 |
Angiotensin (1-9)
|
|
decreases_activity of
|
response to oxidative stress
|
|
| 118127 |
Angiotensin (1-9)
|
|
increases_activity of
|
thrombosis
|
|
| 118128 |
Angiotensin (1-9)
|
|
decreases_quantity of
|
Tissue plasminogen activator
|
in blood plasma
|
| 118129 |
Angiotensin (1-9)
|
|
increases_quantity of
|
SERPINE1
|
in blood plasma
|
|
30934934
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
12,056
|
| 118346 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 118347 |
ACE
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
| 118348 |
MME
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
| 118351 |
Angiotensin (1-9)
|
|
increases_activity of
|
Bradykinin
|
|
| 118352 |
Angiotensin (1-9)
|
|
increases_activity of
|
NO
|
|
| 118353 |
Angiotensin (1-9)
|
|
increases_activity of
|
arachidonic acid secretion
|
|
| 118354 |
Angiotensin (1-9)
|
|
affects_activity of
|
blood platelet
|
|
|
19065996
|
Diabetes mellitus, type II
Insulin resistance
|
|
12,092
|
| 118758 |
Angiotensin (1-9)
|
|
increases_activity of
|
thrombosis
|
via AGTR1
|
| 118759 |
Angiotensin (1-9)
|
|
decreases_quantity of
|
PLAT
|
in blood plasma; via AGTR1
|
| 118760 |
Angiotensin (1-9)
|
|
increases_quantity of
|
SERPINE1
|
in blood plasma; via AGTR1
|
| 118761 |
Angiotensin (1-9)
|
NOT |
interacts (colocalizes) with
|
AGTR1
|
|
|
23884911
|
Cardiovascular disease
|
|
12,181
|
| 119457 |
Angiotensin (1-9)
|
|
decreases_activity of
|
hypertension
|
via AGTR2
|
| 119458 |
Angiotensin (1-9)
|
|
decreases_activity of
|
cardiac hypertrophy
|
via AGTR2
|
| 119459 |
Angiotensin (1-9)
|
|
decreases_activity of
|
aortic hypertrophy
|
via AGTR2
|
| 119461 |
Angiotensin (1-9)
|
|
decreases_activity of
|
fibrosis
|
via AGTR2
|
| 119462 |
Angiotensin (1-9)
|
|
decreases_activity of
|
response to oxidative stress
|
via AGTR2
|
| 119463 |
Angiotensin (1-9)
|
|
increases_quantity of
|
Collagen
|
via AGTR2
|
| 119464 |
Angiotensin (1-9)
|
|
decreases_expression of
|
TGFB1
|
via AGTR2
|
|
24463937
|
Cardiovascular disease
|
|
12,194
|
| 119778 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 119779 |
Angiotensin I
|
|
increases_quantity of
|
Angiotensin (1-9)
|
via ACE2
|
|
32127770
|
Neurodegenerative disorder
|
|
14,078
|
| 133026 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 133047 |
Angiotensin (1-9)
|
|
increases_activity of
|
AGTR2
|
|
|
32264791
|
COVID-19
|
|
14,143
|
| 133668 |
Angiotensin (1-9)
|
|
increases_expression of
|
LNPEP
|
in LNCaP cells, in PC3 cells
|
| 133672 |
Angiotensin (1-9)
|
|
increases_expression of
|
RELA
|
in PC3 cells
|
| 133674 |
Angiotensin (1-9)
|
|
increases_expression of
|
RELB
|
in PC3 cells
|
| 133681 |
Angiotensin (1-9)
|
|
decreases_expression of
|
HIF1A
|
in LNCaP cells
|
| 133687 |
Angiotensin (1-9)
|
|
decreases_expression of
|
BAD
|
in LNCaP cells
|
| 133688 |
Angiotensin (1-9)
|
|
increases_expression of
|
AR
|
in PC3 cells
|
| 133691 |
Angiotensin (1-9)
|
|
decreases_expression of
|
CYP11A1
|
in LNCaP cells
|
| 133692 |
Angiotensin (1-9)
|
|
decreases_expression of
|
CYP17A1
|
in PC3 cells
|
| 133693 |
Angiotensin (1-9)
|
|
decreases_expression of
|
HSD17B3
|
in PC3 cells, in LNCaP cells
|
| 133696 |
Angiotensin (1-9)
|
|
affects_activity of
|
inflammatory response
|
in prostate cancer cells
|
| 133697 |
Angiotensin (1-9)
|
|
affects_activity of
|
steroid biosynthetic process
|
in prostate cancer cells
|
|
32872192
|
Prostate cancer
|
|
14,302
|
| 134961 |
ACE
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
|
32305401
|
Cardiovascular disease
COVID-19
|
|
14,452
|
| 136404 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
in kidney
|
|
26995300
|
Renal
|
CIDeRplus